RETURN II: Efficacy and tolerability of subcutaneous interferon beta 1a (REBIF) in patients with relapsing multiple sclerosis following discontinuation of natalizumab

Trial Profile

RETURN II: Efficacy and tolerability of subcutaneous interferon beta 1a (REBIF) in patients with relapsing multiple sclerosis following discontinuation of natalizumab

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2015

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms RETURN-II
  • Sponsors Merck Serono
  • Most Recent Events

    • 17 Aug 2015 New trial record
    • 23 Jun 2015 Results presented at the 1st Congress of the European Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top